Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $1.741 million which beat the analyst consensus estimate of $1.535 million by 13.42 percent. This is a 43.36 percent decrease over sales of $3.074 million the same period last year.